



DIAGNOSTIC  
PATHOLOGY  
MEDICAL  
GROUP, INC.

**NEW MSI TESTING ON BIOPSIES WITH NEWLY  
DIAGNOSED ENDOMETRIAL CARCINOMA**



May 27, 2016

Dear Valued Client:

Universal testing of endometrial carcinoma for microsatellite instability (MSI) has been advocated by the Society of Gynecologic Oncology and they have put forward the following statement:

*“All women who are diagnosed with endometrial cancer should undergo systematic clinical screening for Lynch syndrome (review of personal and family history) and/or molecular screening. Molecular screening of endometrial cancers for Lynch syndrome is the preferred strategy when resources are available.”*

The National Comprehensive Cancer Network (NCCN) recommends Lynch syndrome screening in patients who are younger than 50 years or meet the Amsterdam or Bethesda criteria.

Diagnostic Pathology Medical Group (DPMG) will perform MSI testing, including immunohistochemical (IHC) stains for mismatch repair (MMR) proteins MLH1, MSH2, MSH6, and PMS2, on all biopsies with newly diagnosed endometrial carcinoma. If there is loss of MLH1 expression, reflex testing for tumor MLH1 hypermethylation will be performed.

MSI testing will not be performed up front on resection specimens, as we do not want to duplicate testing that may have already been performed on a biopsy at an outside institution. MSI testing on resection specimens can be performed upon written request.

If you have any questions, please contact DPMG customer service at 916-446-0424.

Thank you,

Cynthia Gasper, MD  
DPMG